TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Regeneus Ltd. ( (AU:CMB) ) just unveiled an announcement.
Cambium Bio Limited has signed a licensing agreement with Keke Medtech, Inc. to develop and commercialize its fibrin biologic for dental applications, marking a significant milestone for the company. This deal not only provides Cambium with non-dilutive funding but also validates its human platelet lysate technology, allowing the company to focus on its primary dry eye disease program while expanding its platform’s potential in complementary areas.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company specializing in the development of human platelet lysate-derived biologics. The company focuses on creating therapeutic products for various medical fields, including ophthalmology, orthopedics, wound healing, and dentistry.
Average Trading Volume: 15,357
Technical Sentiment Signal: Sell
Current Market Cap: A$10.74M
For an in-depth examination of CMB stock, go to TipRanks’ Overview page.